SEC Form 4 · accession 0001333277-18-000035
CymaBay Therapeutics, Inc. · CBAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Goldfischer
Director
Period of report
Mar 22, 2018
Accepted (ET)
Mar 23, 2018 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001042074
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 22, 2018 | M | 9,340 | $5.00 | A | 9,340 | D | |
| Common Stock | Mar 22, 2018 | M | 5,660 | $5.50 | A | 15,000 | D | |
| Common StockF1 | Mar 22, 2018 | S | 15,000 | $13.025 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.00 | Mar 22, 2018 | M | 6,470 | D | — | Oct 30, 2023 | Common Stock | 6,470 | 0 | D |
| Stock Option (right to buy)F2 | $5.00 | Mar 22, 2018 | M | 2,870 | D | — | Jan 5, 2024 | Common Stock | 2,870 | 0 | D |
| Stock Option (right to buy)F3 | $5.50 | Mar 22, 2018 | M | 5,660 | D | — | Jun 27, 2027 | Common Stock | 5,660 | 9,340 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.00 to $13.15, inclusive. The reporting person undertakes tp provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2Fully vested.
- F3The option vests as to 1/12 of the underlying shares monthly from June 1, 2017.